Skin Cancer

In a phase 3 trial, binimetinib is showing promise for some melanoma patients who had disease progression on immunotherapy.

Support groups aren't for everyone, but finding even one other patient or survivor you can relate to can make all the difference in not feeling completely isolated.

Breast cancer and melanoma survivor tries to help her mom with breast cancer treatment choices.

Breast cancer survivor Barbara Tako recalls a Fourth of July holiday during her chemotherapy treatments.

In recent years, concern has grown over the ultraviolet (UV) lights used to dry the gel nail polish. They give off UVA rays, which cause aging and skin cancer.

Early detection of new or recurrent melanoma can be aided by checking skin with a partner who has been trained to identify concerning moles on the body.

Deciding on treatment for melanoma does not have to be a guessing game, says Keith T. Flaherty.

Why don't I feel myself? Why do so many of us (survivors) still say that months and years out, asks Barbara Tako

Breast cancer and melanoma survivor has many birthday wishes when she blows the candles out on her birthday cake.

A small, early trial demonstrated that a combination of Imlygic and Keytruda can have clinical benefit for patients with advanced melanoma.

Binimetinib, an experimental targeted drug, reduced the risk of disease progression or death in patients with NRAS-mutant metastatic melanoma in a recent phase 3 study.

Surgery is still the most promising treatment option for many patients with melanoma, says Giorgos C. Karakousis.

Checkpoint blockade immunotherapies like Keytruda are increasing the OS rates for patients with advanced melanoma.

Melanoma cancer survivor is grateful and feels like she discovered that she is allergic to air.

Patients with melanoma who were treated with a combination of Opdivo and Yervoy showed no significant changes in their quality of life when compared to those who were treated with either agent alone.

Why is the development of vitiligo a predictor of good response in patients taking immunotherapy for melanoma, and what can scientists learn from this?

Triple wild-type melanoma may not respond to approved targeted drugs, but immunotherapy can be an excellent option.

In the fast-moving world of melanoma treatment, new therapeutic options for patients with metastatic disease are emerging faster than oncology researchers can establish guidelines for their optimal clinical use. That is raising questions about which should be the firstline choice in metastatic melanoma — targeted drugs or immunotherapy — and how these drugs should be sequenced.